Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969078 | 0.84 | ALDH1A1 (0.53) | PTGS2ALDH1A1TSHRAOX1HPGD | |
| SCHEMBL990491 | 0.82 | PTGS2 (0.40) | PTGS2ALDH1A1AOX1HPGD | |
| SCHEMBL989200 | 0.79 | PTGDR2 (0.39) | ALDH1A1MEN1POLBKMT2ABRD4 | |
| SCHEMBL7754930 | 0.79 | PTGS2 (0.39) | PTGS2ALDH1A1TSHRAOX1HPGD | |
| SCHEMBL3924578 | 0.78 | ALDH1A1 (0.56) | ALDH1A1TSHRAOX1HPGDMEN1 | |
| SCHEMBL3920365 | 0.77 | ALDH1A1 (0.70) | ALDH1A1TSHRAOX1HPGDFDPS | |
| SCHEMBL2775394 | 0.76 | ALDH1A1 (0.45) | ALDH1A1POLBKMT2A | |
| SCHEMBL3920869 | 0.73 | ALDH1A1 (0.58) | ALDH1A1TSHRAOX1HPGDFDPS | |
| SCHEMBL14610546 | 0.73 | TUBB1 (0.52) | PTGS2ALDH1A1TSHRAOX1HPGD | |
| SCHEMBL5734850 | 0.72 | ALDH1A1 (0.53) | ALDH1A1TSHRAOX1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2011002814-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002814-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | HSD17B12, CYP2A13, CYP27A1 | PTGS2 403/4885ALDH1A1 205/4885TSHR 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.